Adamis Pharmaceuticals Corporation (ADMP) is a leading drug manufacturers-specialty & generic business based in the US. It opened the day at $0.7909 after a previous close of $0.78. During the day the price has varied from a low of $0.7602 to a high of $0.8184. The latest price was $0.8048 (25 minute delay). Adamis Pharmaceuticals is listed on the NASDAQ and employs 131 staff. All prices are listed in US Dollars.
Since the stock market crash in March caused by coronavirus, Adamis Pharmaceuticals's share price has had significant positive movement.
Its last market close was $0.87, which is 27.05% up on its pre-crash value of $0.6347 and 222.22% up on the lowest point reached during the March crash when the shares fell as low as $0.27.
If you had bought $1,000 worth of Adamis Pharmaceuticals shares at the start of February 2020, those shares would have been worth $534.96 at the bottom of the March crash, and if you held on to them, then as of the last market close they'd be worth $1,308.07.
|52-week range||$0.27 - $1.51|
|50-day moving average||$0.5141|
|200-day moving average||$0.7314|
|Wall St. target price||$1|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||$-0.831|
All investing should be regarded as longer term. The value of your investments can go up and down, and you may get back less than you invest. Past performance is no guarantee of future results. If you’re not sure which investments are right for you, please seek out a financial adviser. Capital at risk.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
|1 week (2021-01-15)||3.18%|
|1 month (2020-12-23)||54.77%|
|3 months (2020-10-23)||1.44%|
|6 months (2020-07-23)||-21.10%|
|1 year (2020-01-23)||10.20%|
|2 years (2019-01-23)||-71.96%|
|3 years (2018-01-23)||-80.61%|
|5 years (2016-01-22)||-81.63%|
|Revenue TTM||$18.4 million|
|Gross profit TTM||$6.3 million|
|Return on assets TTM||-37.61%|
|Return on equity TTM||-102.54%|
|Market capitalisation||$48.5 million|
TTM: trailing 12 months
There are currently 2.4 million Adamis Pharmaceuticals shares held short by investors – that's known as Adamis Pharmaceuticals's "short interest". This figure is 9.1% down from 2.7 million last month.
There are a few different ways that this level of interest in shorting Adamis Pharmaceuticals shares can be evaluated.
Adamis Pharmaceuticals's "short interest ratio" (SIR) is the quantity of Adamis Pharmaceuticals shares currently shorted divided by the average quantity of Adamis Pharmaceuticals shares traded daily (recently around 6.1 million). Adamis Pharmaceuticals's SIR currently stands at 0.4. In other words for every 100,000 Adamis Pharmaceuticals shares traded daily on the market, roughly 400 shares are currently held short.
However Adamis Pharmaceuticals's short interest can also be evaluated against the total number of Adamis Pharmaceuticals shares, or, against the total number of tradable Adamis Pharmaceuticals shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Adamis Pharmaceuticals's short interest could be expressed as 0.03% of the outstanding shares (for every 100,000 Adamis Pharmaceuticals shares in existence, roughly 30 shares are currently held short) or 0.0261% of the tradable shares (for every 100,000 tradable Adamis Pharmaceuticals shares, roughly 26 shares are currently held short).
Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Adamis Pharmaceuticals.
Find out more about how you can short Adamis Pharmaceuticals stock.
We're not expecting Adamis Pharmaceuticals to pay a dividend over the next 12 months. However, you can browse other dividend-paying shares in our guide.
Adamis Pharmaceuticals's shares were split on a 1:17 basis on 13 December 2013. So if you had owned 17 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Adamis Pharmaceuticals shares – just the quantity. However, indirectly, the new 1600% higher share price could have impacted the market appetite for Adamis Pharmaceuticals shares which in turn could have impacted Adamis Pharmaceuticals's share price.
Over the last 12 months, Adamis Pharmaceuticals's shares have ranged in value from as little as $0.27 up to $1.51. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Adamis Pharmaceuticals's is 1.6105. This would suggest that Adamis Pharmaceuticals's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).
Adamis Pharmaceuticals Corporation, a specialty biopharmaceutical company, develops and commercializes products in the therapeutic areas of allergy and respiratory disease in the United States. The company's specialty pharmaceutical product candidates comprise Symjepi (epinephrine) Injection pre-filled syringe (PFS) for use in the emergency treatment of acute allergic reactions, including anaphylaxis. It also offers dry powder inhaler products consisting of fluticasone (APC-4000) for the treatment of asthma; beclomethasone (APC-1000), a metered dose inhaler product for the asthma; Tadalafil (APC-8000) for the treatment of erectile dysfunction; and naloxone injection product candidates (APC-6000) for the treatment of opioid overdose. In addition, the company provides corticosteroids, hormone replacement therapies, hospital outsourcing products, injectables, urological preparations, topical compounds for pain, and men's and women's health products; and certain veterinary pharmaceutical products for animals. Adamis Pharmaceuticals Corporation is headquartered in San Diego, California.
Learn more about Transportation and Logistics Systems’ recent performance and where you can invest in Transportation and Logistics Systems shares. We also run through some helpful rules of thumb for any investor.
Learn more about Charlie’s Holdings’ recent performance and where you can invest in Charlie’s Holdings shares. We also run through some helpful rules of thumb for any investor.
Learn more about Lemonade’s recent performance and where you can invest in Lemonade shares. We also run through some helpful rules of thumb for any investor.
Learn more about Unity Software’s recent performance and where you can invest in Unity Software shares. We also run through some helpful rules of thumb for any investor
Learn more about FuelCell Energy’s recent performance and where you can invest in FuelCell Energy shares. We also run through some helpful rules of thumb for any investor.
Learn more about CloudCommerce’s recent performance and where you can invest in CloudCommerce shares. We also run through some helpful rules of thumb for any investor
Ever wondered how to buy shares in Zomedica Pharmaceuticals? We explain how and compare a range of providers that can give you access to many brands, including Zomedica Pharmaceuticals.
Ever wondered how to buy shares in YRC Worldwide? We explain how and compare a range of providers that can give you access to many brands, including YRC Worldwide.
Ever wondered how to buy shares in Xeros Technology Group? We explain how and compare a range of providers that can give you access to many brands, including Xeros Technology Group.
Ever wondered how to buy shares in Xpediator? We explain how and compare a range of providers that can give you access to many brands, including Xpediator.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.